Senti Bio Awarded $8 Million Grant from California Institute for Regenerative Medicines for Clinical Development of Logic Gated CAR-NK Cell Therapy

Senti Biosciences, Inc. (Nasdaq: SNTI) has announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia.